Aims-To evaluate serum glutathione Stransferase B, (GST B1), a highly sensitive test of hepatocellular function, as a means of identifying liver disease in patients with cystic fibrosis (CF). Methods-The presence of liver disease was sought over a three year period in 60 children with CF, using a combination of clinical assessment, ultrasound examination, conventional biochemical tests ofliver function (LFTs), and measurement of GST B1. Results-Reference ranges for serum GST B1 were established in a paediatric control population. The 95% value (4 55 pgl1) was similar to the upper limit of normal previously derived in adults. Mean (SE) serum GST B1 activities were higher in the CF population (9.0 (1.14) pgl1) than in age matched controls (2.4 (0.15) ttgl1). Ten patients with CF showed clinical signs of liver dysfunction. All but one had a serum GST B1 >4-55 tgIl. Twelve other patients had elevated LFTs without clinically evident liver dysfunction, six had abnormal ultrasound scans and two showed both of these anomalies. Thirty patients with CF had neither biochemical, ultrasonographic nor clinical signs of liver disease. On review three years later, clinically important liver disease was reaffirmed in eight ofthe 10 index cases and had become apparent in a further eight, all of whom had elevated GST B1 activities. Five (36%) of the patients with elevated LFTs and two (33%) with isolated ultrasound changes continued to show these abnormalities. Conclusions-The limitations of conventional LFTs and ultrasound scans were evident from this study. The results suggest that elevated GST B1 activities may be a better predictor ofhepatic dysfunction in CF than conventional LFTs. (J7 Clin Pathol 1995;48:771-774) 
graphic nor clinical signs of liver disease. On review three years later, clinically important liver disease was reaffirmed in eight ofthe 10 index cases and had become apparent in a further eight, all of whom had elevated GST B1 activities. Five (36%) of the patients with elevated LFTs and two (33%) with isolated ultrasound changes continued to show these abnormalities. Conclusions-The limitations of conventional LFTs and ultrasound scans were evident from this study. The results suggest that elevated GST B1 activities may be a better predictor ofhepatic dysfunction in CF than conventional LFTs. Liver involvement occurs in 20-50% ofpatients with cystic fibrosis, depending on age and the type ofpathology recognised.' 2 Steatosis, which is independent of age, occurs in one third of patients' but may regress with improved nutrition. Focal biliary cirrhosis, which is pathognomonic of cystic fibrosis,3 shows an increasing incidence with age, rising from 10% in children dying within the first three months to 27% in children dying after the first year. 4 Perhaps 5% of children with focal biliary cirrhosis will go on to develop multinodular cirrhosis.
The prevalence of clinically apparent liver disease also shows a progressive increase with age to a peak of 8-7% in [16] [17] [18] [19] [20] year olds2 and appears to be unrelated to the severity ofdisease elsewhere. cut off value with a high sensitivity should be applied. Thus, a cut off value at the upper ol serum samples (males 2 15 +0 9 ,ug/l, reference limit for serum GST B, (4-55 gg/l) les 2-8 + 1 4 gg/l, p = 0 03); the results would give a sensitivity of 97% and a specificity oth paired and unpaired subjects were of 50% in the present study. This represents fore pooled for both groups. Mean (SE) the detection ofliver disease in all ofthe patients n GST B1 activities were significantly with cystic fibrosis who manifested disease r (p<00O1) in patients with cystic fibrosis three years later at the cost of suspecting liver (114) ,g/l) compared with controls (2-4 disease in 18 patients who remained asymptoi),g/l). Significant correlations existed in matic. Alternatively, if treatment options for ystic fibrosis group between GST B1 and liver disease in cystic fibrosis are considered ne aminotransferase (ALT), aspartate limited and the main purpose of the test is to otransferase (AST) and y-glutamyl-reassure patients who are unlikely to develop ferase (yGT) (r=0-6, 0 5 and 0 3, re-liver dysfunction, a cut off value at a higher -ively). specificity can be selected from the ROC curve Le 95% value for serum GST B1 was cal- (fig 2) or from table 2. A cut off value at 10 pg/ ed for the controls. The derived value 1 would, for example, have missed five cases of gg/l) was similar to the upper limit of liver disease in the present study but the numal previously established in adult studies ber of false positive results would have de- (1) .1 Four patients with cystic fibrosis gave creased to three. If serum GST B, activities ts above the top serum GST B1 standard predict liver disease in cystic fibrosis over a vgil) but were assigned this value for data period greater than three years, it would be rsis.
expected that the above indexes of test pern patients with cystic fibrosis with clinical formance should further improve with addisease (persistent hepatosplenomegaly ditional follow up. or without oesophageal varices) were iden-
The limitations ofconventional liver function at the onset of the study. All but one had tests are also evident from this study. Conum GST B1 activity >4 55 gg/l (table 1, founding factors include the effect of drug ). On review three years later, eight of therapy on yGT, and of differential isoenzymes adex cases were still considered clinically on alkaline phosphatase (ALP). Specific and rmal, but one patient with a GST B1 suitable ALP isoenzymes such as the high molity of 5-2 1tg/l and the child with a normal ecular mass (biliary) form have, however, been BI activity (1 9 gg/l) no longer exhibited used as a marker of liver disease in cystic of liver disease. During the study period, fibrosis. With this assay, Schoenau et al15 found al evidence of liver dysfunction became similar differences between children with cystic rent in a further eight patients, all ofwhom fibrosis and controls to those demonstrated .levated GST B1 activities at the first ex-with serum GST B1 in this study, although no ation ( We thank Dr R J Pollitt of the Regional Neonatal Screening Unit for radioactive counting facilities and Dr K Levick for his assistance with the ultrasonic examinations. We thank the CHRIS fund for their financial support.
